Dr. Thomas Flaig, MD
Hematology & Oncology (Hematology & Oncology Physician)
12605 E 16th Ave
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Minnesota Medical School (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 86
Licensed in Colorado since 2006, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: University of Minnesota Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CO license 44457 (first issued 2006; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Colorado Hospital Authority Aurora, CO
- Medical Center of the Rockies Loveland, CO
- Uchealth Highlands Ranch Hospital Highlands Ranch, CO
- Longs Peak Hospital Longmont, CO
- Uchealth Broomfield Hospital Broomfield, CO
Medical groups
- University Physicians Incorporated (3,215 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 86
- Services billed
- 363
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 108 | 47 |
| Established patient office or other outpatient visit, 30-39 minutes | 74 | 44 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 80 |
| Xtandi (enzalutamide) | 37 |
| Prednisone Other prescribers in Aurora, CO | 33 |
| Lynparza (olaparib) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $224 in total to this clinician.
| Taiho Oncology, Inc. | $140 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $84.32 |
| Speaking at a medical education program | $208 |
|---|---|
| Travel and Lodging | $16.08 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Taiho Oncology, Inc. Mar 29, 2025 | Speaking at a medical education program | $124 |
| AstraZeneca Pharmaceuticals LP Mar 29, 2025 | Speaking at a medical education program | $84.32 |
| Taiho Oncology, Inc. May 31, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $10.38 |
| Taiho Oncology, Inc. Apr 30, 2025 | Travel and Lodging travel to Orlando, FL | $2.85 |
| Taiho Oncology, Inc. Apr 30, 2025 | Travel and Lodging travel to Orlando, FL | $2.85 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $797,114 in research payments for these studies, mostly to the institutions running them.
- A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Pros…
AstraZeneca UK Limited - A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Blad…
Merck Sharp & Dohme LLC - A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1,L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma KEYMAKER…
Merck Sharp & Dohme LLC - A Phase 1,2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab plus Enfortumab Vedotin EV in Combination With Investigational Agents versus Pembrolizumab plus EV, as First-Line Treatment f…
Merck Sharp & Dohme LLC - Phase III Ipatasertib plus abiraterone in mCRPC 1st Line
Genentech, Inc. - A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Pfizer Inc. - A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641
Merck Sharp & Dohme LLC - Pan Tumor Rollover Study
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT03899155
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.